Neoprobe's Phase 3 Lymphoseek Study Reaches Accrual Goal

[News]

Neoprobe Corporation (NYSE: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, announced that a multi-center Phase 3 study of Lymphoseek® has enrolled clinical subjects to achieve the minimum analysis goal of 196 lymph nodes, the study's primary accrual objective...

More... (http://mnt.to/f/3RfG)